Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Andrews

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
The American Journal of Tropical Medicine and Hygiene|March 16, 2007
Low-level malaria infections detected by a sensitive polymerase chain reaction assay and use of this technique in the evaluation of malaria vaccines in an endemic areaEgeruan B Imoukhuede, Laura Andrews, Paul Milligan, et al.
The American Journal of Pathology|May 2, 2009
Homeostatic role of transforming growth factor-beta in the oral cavity and esophagus of mice and its expression by mast cells in these tissuesAllison Vitsky, James Waire, Robert Pawliuk, et al.
Nature Reviews. Immunology|September 4, 2012
Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trialChristopher Horvath, Laura Andrews, Andreas Baumann, et al.
Vaccine|April 20, 2011
A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccineDavid W Porter, Fiona M Thompson, Tamara K Berthoud, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 23, 2005
Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus AnkaraDaniel P Webster, Susanna Dunachie, Jenni M Vuola, et al.
Regulatory Toxicology and Pharmacology : RTP|November 22, 2011
The design of chronic toxicology studies of monoclonal antibodies: implications for the reduction in use of non-human primatesKathryn L Chapman, Laura Andrews, Jeffrey J Bajramovic, et al.
Plos One|January 31, 2008
Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trialFiona M Thompson, David W Porter, Shinji L Okitsu, et al.
Immunity|September 20, 2005
Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infectionMichael Walther, Jon Eric Tongren, Laura Andrews, et al.
Infection and Immunity|April 20, 2006
Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite proteinMichael Walther, Fiona M Thompson, Susanna Dunachie, et al.
The Journal of Infectious Diseases|April 11, 2013
Comparison of modeling methods to determine liver-to-blood inocula and parasite multiplication rates during controlled human malaria infectionAlexander D Douglas, Nick J Edwards, Christopher J A Duncan, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
The American Journal of Tropical Medicine and Hygiene|March 16, 2007
Low-level malaria infections detected by a sensitive polymerase chain reaction assay and use of this technique in the evaluation of malaria vaccines in an endemic areaEgeruan B Imoukhuede, Laura Andrews, Paul Milligan, et al.
The American Journal of Pathology|May 2, 2009
Homeostatic role of transforming growth factor-beta in the oral cavity and esophagus of mice and its expression by mast cells in these tissuesAllison Vitsky, James Waire, Robert Pawliuk, et al.
Nature Reviews. Immunology|September 4, 2012
Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trialChristopher Horvath, Laura Andrews, Andreas Baumann, et al.
Vaccine|April 20, 2011
A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccineDavid W Porter, Fiona M Thompson, Tamara K Berthoud, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 23, 2005
Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus AnkaraDaniel P Webster, Susanna Dunachie, Jenni M Vuola, et al.
Regulatory Toxicology and Pharmacology : RTP|November 22, 2011
The design of chronic toxicology studies of monoclonal antibodies: implications for the reduction in use of non-human primatesKathryn L Chapman, Laura Andrews, Jeffrey J Bajramovic, et al.
Plos One|January 31, 2008
Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trialFiona M Thompson, David W Porter, Shinji L Okitsu, et al.
Immunity|September 20, 2005
Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infectionMichael Walther, Jon Eric Tongren, Laura Andrews, et al.
Infection and Immunity|April 20, 2006
Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite proteinMichael Walther, Fiona M Thompson, Susanna Dunachie, et al.
The Journal of Infectious Diseases|April 11, 2013
Comparison of modeling methods to determine liver-to-blood inocula and parasite multiplication rates during controlled human malaria infectionAlexander D Douglas, Nick J Edwards, Christopher J A Duncan, et al.
Pageof 8